AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02492230
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin dose adjusted to maintain INR 2.0-3.0 for all period of study; Aspirin dose-75mg for 45 days after randomization; Clopidogrel dose-75mg for 6 months after procedure.~All drugs will be started before PCI procedure. Low molecular weight heparins will be used before procedure and will be stopped when INR reach 1.8-2.0.
Trial: NCT02658877
Drug: Omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient's pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.
Trial: NCT01290276
Drug: Ond-PR1
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1)
Trial: NCT01290276
Drug: Ond-PR1 + MPh-IR
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1) plus 10 mg methylphenidate immediate release (Mph-IR)
Trial: NCT01290276
Drug: Ond-PR2
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of 8 mg ondansetron pulsatile-release formulation 2 (Ond-PR2)
Trial: NCT01290276
Drug: Ond-PR2 +_ MPh-IR
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of 8 mg of ondansetron pulsatile-release formulation 2 (Ond-PR2) plus 10 mg methylphenidate immediate release (Mph-IR)
Trial: NCT04366713
Drug: Neratinib
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered orally once daily as a single daily dose of 240 mg
Trial: NCT01548859
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.2 mg/kg/saat continuous infusion of midazolam received during anaesthesia
Trial: NCT00959686
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles
Trial: NCT01548859
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: end tidal concentration of % 0,5-8
Trial: NCT00354757
Drug: rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03638076
Drug: GLS4
RxNorm normalized name: Galsulfase
DrugBank: Galsulfase (DB01279)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subject in group A will receive Mesilate Capsule 120mg twice daily. Subject in group B will receive Mesilate Capsule 120mg three times daily.
Trial: NCT03120468
Drug: Topiramate and Placebo
RxNorm normalized name: phentermine and topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate up to 200 mg/day and Placebo for 12 weeks
Trial: NCT00043888
Drug: fosamprenavir
RxNorm normalized name: Fosamprenavir
DrugBank: Fosamprenavir (DB01319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00043888
Drug: COMBIVIR
RxNorm normalized name: Combivir
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00043888
Drug: ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00043888
Drug: TRIZIVIR
RxNorm normalized name: Trizivir
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00428064
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00428064
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00026520
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03289351
Drug: Piperacillin, Tazobactam Drug Combination
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single drug therapy
Trial: NCT00335140
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 g/m2/day in 500 cc D5W IV over 2 hrs. x 2 doses 24hrs. apart, Weeks 11, 14
Trial: NCT00641186
Drug: sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4.5 to 9.0 grams per night
Trial: NCT00335140
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 16mg (week 1) PO daily Weeks 1, 2, 3, 4, 5, 6 Taper by 4 mg/wk, weeks 2, 3, by 2 mg/wk week 4, 5, 6
Trial: NCT00335140
Drug: Procarbazine
RxNorm normalized name: Procarbazine
DrugBank: Procarbazine (DB01168)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/m2 PO daily x 7 days Weeks 1, 5, 9
Trial: NCT00335140
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4 mg/m2 IV push, Weeks 1, 3, 5, 7, 9 2m2 (2.8 mg) dose cap
Trial: NCT03901716
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in all groups received midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
Trial: NCT04366713
Drug: Loperamide
RxNorm normalized name: Loperamide
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally for prophylaxis for 28 days and then as needed
Trial: NCT00822315
Drug: efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tenofovir 245 mg / lamivudine 300 mg / efavirenz 600 mg
Trial: NCT00822315
Drug: raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tenofovir 245 mg / lamivudine 300 mg / raltegravir 400 mg
Trial: NCT00822315
Drug: raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tenofovir 245 mg / lamivudine 300 mg / raltegravir 800 mg
Trial: NCT05433896
Drug: Dasatinib ASD
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: XS004 Dasatinib Amorphous Solid Dispersion Film-Coated Tablet, 90 mg Test Formulation
Trial: NCT05433896
Drug: Omeprazole 40 MG
RxNorm normalized name: omeprazole 40 MG
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole Delayed Release Capsules, USP 40 mg
Trial: NCT03489850
Drug: Ibudilast
RxNorm normalized name: ibudilast
DrugBank: Ibudilast (DB05266)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.
Trial: NCT04334512
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with hydroxychloroquine
Trial: NCT00737477
Drug: Methoxy polyethylene glycol-epoetin beta
RxNorm normalized name: Methoxy polyethylene glycol-epoetin beta
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mircera will be administered SC every 4 weeks for a total of 48 weeks. The first dose of 120 or 200 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
Trial: NCT01370655
Drug: MK-7145
RxNorm normalized name: MK-7145
DrugBank: MK-7145 (DB11968)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01370655
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01370655
Drug: Placebo to MK-7145
RxNorm normalized name: MK-7145
DrugBank: MK-7145 (DB11968)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01923467
Drug: Nicotine patches 21 mg
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eligible participants will receive a 2-week supply of Nicoderm CQ Step 1 patches to help them be successful in their quit attempt.
Trial: NCT00333086
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03106753
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intrathecal bupivacaine 7.5 mg
Trial: NCT03106753
Drug: Terbutaline
RxNorm normalized name: Terbutaline
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25 mg Terbutaline subcutaneously
Trial: NCT02470780
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin is an antibiotic used to treat SIBO. It is a 7-day course of treatment followed by three or six months of follow-up. This is a placebo-controlled study designed so that all participants will receive the active drug at least once during the study.
Trial: NCT01518959
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180.000 IU monthly
Trial: NCT01518959
Drug: oleum neutralicum
RxNorm normalized name: Oleum ricini
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator, 9 ml monthly
Trial: NCT00742326
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 45 mg/daily
Trial: NCT01285700
Drug: Lamazym
RxNorm normalized name: Lamazym
DrugBank: Velmanase alfa (DB12374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERT, infusion weekly
Trial: NCT01931098
Drug: topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taken .25 mg orally, daily continuous until progression up to one year.
Trial: NCT01931098
Drug: pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 600 mg orally, daily until progression, up to one year.
Trial: NCT02268994
Drug: ferric citrate
RxNorm normalized name: Ferric Citrate
DrugBank: Ferric sulfate (DB11171)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 g ferric citrate containing approximately 210 mg of ferric iron
Trial: NCT02405598
Drug: Salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Albuterol Syrup (1mL= Salbutamol 0.4mg, 60ml/bot)~2. VENTOLIN TABLETS 2MG (SALBUTAMOL SULPHATE)
Trial: NCT03864926
Drug: Envarsus XR
RxNorm normalized name: Envarsus XR
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Envarsus XR is FDA approved for the prophylaxis of organ rejection in kidney transplant recipients converted from tacrolimus immediate-release formulations, in combination with other immunosuppressants. Envarsus XR, is designed to deliver tacrolimus more smoothly over the whole day.~Envarsus XR, a calcineurin-inhibitor immunosuppressant, is available for oral administration as extended-release tablets containing the equivalent of 0.75 mg, 1 mg, or 4 mg of anhydrous tacrolimus USP. Inactive ingredients include hypromellose USP, lactose monohydrate NF, polyethylene glycol NF, poloxamer NF, magnesium stearate NF, tartaric acid NF, butylated hydroxytoluene NF, and dimethicone NF. Tacrolimus is the active ingredient in ENVARSUS XR.
Trial: NCT02650713
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion.
Trial: NCT03864926
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (generic; immediate release) is FDA approved for the prophylaxis of organ rejection in heart, kidney and liver transplant recipients.
Trial: NCT02650713
Drug: RO6958688
RxNorm normalized name: Anti-cea/cd3 bispecific antibody ro6958688
DrugBank: Cibisatamab (DB17349)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO6958688 is administered by IV infusion~In Part IA: RO6958688 is administered weekly (QW) on days 1,8 and 15 of each 21-day cycle.~In Part 1b: RO6958688 is administered weekly (QW) or every 3 weeks (Q3W). Cohort A: RO6958688 starting dose will be 100 mg either QW or Q3W.~Step Up dose cohorts: RO6958688 starting dose will be 40mg and increase with each administration up to the MTD or 1200 mg whichever is lower.
Trial: NCT02635893
Drug: D-Cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg of Seromycin by mouth will be administered
Trial: NCT02326844
Drug: BMN 673 (talazoparib)
RxNorm normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg by mouth (p.o.) once daily on 28-day cycles until disease progression
Trial: NCT02765555
Drug: RBP-7000
RxNorm normalized name: COCAINE ESTERASE (RBP-8000)
DrugBank: COCAINE ESTERASE (RBP-8000) (DB19225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT02948348
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Capecitabine:Dose of 1650mg/m2,14days, Radiation:45Gy/25 fractions, Nivolumab :240mg on day1 of each cycle, Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR).
Trial: NCT02948348
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For only Cohort D,1 mg/kg at six-week intervals
Trial: NCT01495221
Drug: Alfilbercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients will receive 2.0 mg intravitreal aflibercept injection.
Trial: NCT01264432
Drug: Veliparib
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02461004
Drug: CKD-391
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product is prescribed to all of radomized subjects for two times.
Trial: NCT02461004
Drug: Atrovastatin and Ezetimibe combination therapy
RxNorm normalized name: atorvastatin and ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Investigational products are prescribed to all of radomized subjects for two times.
Trial: NCT01448499
Drug: Clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: escalating dose of clozapine up to 900 mg/day
Trial: NCT02459457
Drug: Paclitaxel and Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients get Paclitaxel and Cisplatin according to protocol
Trial: NCT02459457
Drug: Paclitaxel and Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients get Paclitaxel and Carboplatin according to protocol
Trial: NCT03042923
Drug: lactulose:mannitol (L:M) oral challenge
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03225690
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prevention of remifentanil induced hyperalgesia
Trial: NCT03225690
Drug: Serum physiologic
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For placebo, serum physiologic will use
Trial: NCT00573742
Drug: Candesartan Cilexeotil 16mg
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan (DB13919)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01448499
Drug: Amisulpride
RxNorm normalized name: Amisulpride
DrugBank: Amisulpride (DB06288)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: escalating dose of amisulpride up to 800 mg/day
Trial: NCT00477490
Drug: desmopressin acetate
RxNorm normalized name: Desmopressin Acetate
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral lyophilisate of desmopressin acetate placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime in the assigned dosage: 10, 25, 50 or 100 μg
Trial: NCT00521157
Drug: Go Medical Naltrexone implants
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone implants 3.2 g (double of 1,6 g)
Trial: NCT01068665
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
Trial: NCT01068665
Drug: insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
Trial: NCT02807272
Drug: Tipifarnib
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT04324463
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral medication
Trial: NCT04324463
Drug: Interferon-Beta
RxNorm normalized name: Interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT04324463
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral medication
Trial: NCT01448499
Drug: Clozapine+Amisulpride
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: augmentation of clozapine with amisulpride
Trial: NCT04324463
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral medication
Trial: NCT02498782
Drug: Fexinidazole
RxNorm normalized name: fexinidazole
DrugBank: Fexinidazole (DB12265)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00743587
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral, 1 x 20mg controlled-release tablets
Trial: NCT00743587
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral, 2 x 50mg immediate release capsules
Trial: NCT00485576
Drug: eculizumab
RxNorm normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: eculizumab 600 mg or matching placebo iv infusion.
Trial: NCT01621776
Drug: Apidra
RxNorm normalized name: Apidra
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects on this treatment arm will receive Apidra insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
Trial: NCT01621776
Drug: Humalog
RxNorm normalized name: HumaLOG
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects on this treatment arm will receive Humalog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
Trial: NCT01621776
Drug: Novolog
RxNorm normalized name: NovoLog
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects on this treatment arm will receive Novolog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians. (NOTE: This arm was only for one year of the study which was the 2012 camp session.)
Trial: NCT03693976
Drug: Xylometazoline Nasal Spray
RxNorm normalized name: xylometazoline Nasal Spray
DrugBank: Xylometazoline (DB06694)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application of Xylometazoline Nasal Spray in accordance with the instructions for use
Trial: NCT00237536
Drug: Lonidamine
RxNorm normalized name: lonidamine
DrugBank: Lonidamine (DB06266)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00641160
Drug: vinorelbine tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose Level #1 PO for at least 7 days
Trial: NCT00641160
Drug: vinorelbine tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose Level #2 PO for at least 7 days
Trial: NCT00641160
Drug: vinorelbine tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose Level #3 PO for at least 7 days
Trial: NCT00273962
Drug: ipratropium plus salbutamol UDV
RxNorm normalized name: salbutamol and ipratropium bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no